CD19 and B-cell non-Hodgkin lymphoma: In a clinical trial, 32 patients of non-Hodgkin B-cell lymphoma treated with CD19 CAR-T cells in a 1:1 ratio of CD8+/CD4+ T cells exhibit long duration of CAR-T cells and have slow disease progression [152].